NPI | Name | Type | Address |
---|---|---|---|
PHARMD Rose Cheng |
Individual |
10 Summer Street Apt 304 Malden, MA |
|
PHARMD Khuyen Kieu Le |
Individual |
7300 N Fresno St Fresno, CA |
|
DR. PHARMD Caroline Patrice Townley |
Individual |
1 Akron General Ave Akron, OH |
|
PHARMD Benjamin Andrick |
Individual |
100 N Academy Ave Danville, PA |
|
PHARMD Robert Alan Nunan |
Individual |
7777 Forest Ln Ste C707 Dallas, TX |
|
DR. PHARMD Brianne Dixon |
Individual |
1275 York Ave New York, NY |
|
DR. PHARMD Emily Ann Hollinghurst |
Individual |
11234 Anderson St Loma Linda, CA |
|
Jonathan David Wilkie |
Individual |
460 W 10th Ave Room 2118 Columbus, OH |
|
PHARMD Kiersten Williams |
Individual |
460 W 10th Ave Columbus, OH |
|
PHARMD Amy Ly Indorf |
Individual |
825 Eastlake Ave E #msg5-90 Seattle, WA |
|
PHARMD Alexis Jones |
Individual |
101 Manning Dr Chapel Hill, NC |
|
PHARMD Saloni Shah |
Individual |
1 Diamond Hill Rd Berkeley Heights, NJ |
|
DR. PHARMD Jinyao Eileen Chen |
Individual |
1 Medical Center Blvd Winston Salem, NC |
|
DR. PHARMD Jeremy Pappacena |
Individual |
1275 York Ave New York, NY |
|
PHARMD Charlene Claire Kabel |
Individual |
1275 York Ave New York, NY |
|
Erica A Casella |
Individual |
705 White Horse Rd Ste D105 Voorhees, NJ |
|
PHARMD Katelyn Elizabeth Palmer |
Individual |
1 Medical Center Blvd Winston Salem, NC |
|
PHARMD Stacey Lisi |
Individual |
20 Duke Medicine Cir # 5-1 Durham, NC |
|
James Meier |
Individual |
2220 Canterbury Dr Hays, KS |
|
DR. PHARMD Carlo Legasto |
Individual |
460 W 10th Ave Rm C150 Columbus, OH |
Every health care provider, whether it’s a hospital, pharmacy, or individual specialist, must obtain their own NPI number. This identification number is unique and is assigned upon application. In tod...
Taxonomy Code | 1835X0200X |
Specialization | Oncology |
Display Name | Oncology Pharmacist |
Taxonomy Group | Pharmacy Service Providers |
Taxonomy Classification | Pharmacist |
Definition | A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases. |
Effective Date | September 30, 2009 |